As per the research report, the size of the Europe Viral Inactivation Market is valued at USD 135.26 million in 2022 and is estimated to be growing at a CAGR of 12.1%, to reach USD 239.44 million by 2027 during the forecast period 2022 to 2027.
Rapid expansion in the pharmaceutical and biotechnology industries, increased government funding, and an increasing number of new drug launches are the primary drivers of the European market. Companies focused on developing technologically enhanced products in Nano filtration technology are projected to boost viral clearance demand. In addition, healthcare spending has increased as chronic diseases like diabetes, cancer, autoimmune disorders, and other diseases have grown regionally.
To combat these diseases, an increase in healthcare spending is mainly required to conceive and develop new and improved therapies. To avoid contamination and fatalities after human eating, viral inactivation is a critical technique that must follow throughout the preparation of these products. One of the major factors encouraging the need for viral inactivation is growing worries about the transmission of blood-borne viruses through plasma-derived medicinal products.
Several techniques for viral inactivation are presently used to ensure the safety of blood plasma-derived protein solutions. In the food and beverage business, enhanced viral inactivation technologies and solutions are being used to help restrict the spread of enteric viruses and ensure product safety. This, together with the development of new physical technologies such as supercritical fluids, gas plasma, and pulsed electric fields, is expected to boost the market's dependability, convenience, and applicability of viral inactivation.
The biosimilar manufacturing technique is costly, making it a difficult market for new entrants to break into. Virus protection is critical with this method. Raw material procurement is one of the most pressing concerns for regulators and biopharmaceutical firms. Because large volumes of process fluids and gasses are used to make biologics, viral infection is not uncommon.
These challenges make viral clearance critical, viral inactivation difficult, and the Europe Viral Inactivation Market's growth hampered. The lack of medical competence in this country will further hamper the market growth. An unfavorable reimbursement scenario will further challenge developing and undeveloped economies and a strict regulatory environment.
This research report on the Europe Viral Inactivation Market has been segmented and sub-segmented into the following categories:
By End User:
Geographically, Europe holds the second-largest market share in the global viral inactivation market due to rapid R&D investments in the life sciences and new product releases in the region. Stem cell products are obtained from donors, and the risk of contamination is substantial due to the strict requirements for viral inactivation monitoring. In wealthy countries such as European countries, stem cell research is quickly expanding. This increase has made a significant contribution to the market's growth.
Stem cell research aims to understand human health better and find novel approaches to cure illnesses and disorders. Therefore, the Viral Inactivation Market is expected to be driven by the rising acceptance of innovative pharmaceuticals and guidelines governing the viral security of biologics. In addition, the growth of the Viral Inactivation Market will be fueled by the expansion of the biologics and biosimilar industry, which will employ various viral inactivation techniques such as acidic pH inactivation during the forecast period.
KEY MARKET PLAYERS
Key players operating in the Europe Viral Inactivation Market profiled in this report are Clean Cells, Charles River Laboratories International Inc, Danaher Corporation, Merck KGaA, Parker Hannifin, Red Source Technologies, Sartorius AG, SGS S.A, Texcell Inc, Viral Inactivated Plasma Systems SA, and WuXi Pharma Tech Inc.,
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org